Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TANDEM-IRI-TACE combined with systemic FOLFIRI for colorectal liver metastases after oxaliplatin regimen failure: Phase I dose escalation study

ABSTRACT: Interventions: TACE will be conducted every 5 weeks. Systemic FOLFIRI will be conducted every 2 weeks. Primary outcome(s): Dose Limiting Toxicity,Recommended Dose Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2630698 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phosphorylation of iRhom2 controls stimulated proteolytic shedding by the metalloprotease ADAM17/TACE

Project description:TACE (TNFa Converting Enzyme), is responsible for cleavage (‘shedding’) of membrane-tethered signaling molecules such as TNF of EGFR ligands. TACE interacts with iRhom2, which mediates the exit of TACE from the endoplasmic reticulum. In this study we analyze a new role for iRHOM2, where a fraction of the protein remains in the membrane and the phosphorylation of different residues in its cytoplasmatic tail is necessary for TACE shedding function.

2021-11-03 | PXD007763 | Pride

A Positive Feedback Loop Between TKT and c-Myc Drives TACE Resistance In Hepatocellular Carcinoma

Project description:Hepatocellular carcinoma (HCC) often receives transarterial chemoembolization (TACE), yet clinical benefit is limited by resistance driven by ischemia-induced adaptations. This study explains how transketolase (TKT) in the pentose phosphate pathway (PPP) modulates HCC progression and TACE refractoriness, and clarifies its mechanistic connection to oncogenic signaling.

2026-03-07 | GSE322668 | GEO

Circulating miR-22 predicts TACE response and targets WEE1 in hepatocellular carcinoma

Project description:Transarterial Chemoembolization (TACE) is the standard therapy for intermediate-stage liver cancer, yet high failure rates and a lack of early biomarkers remain significant challenges. Our study shows that circulating miR-22 levels increase significantly within 48 hours in TACE non-responders, providing a much faster alternative to traditional imaging for identifying treatment failure. Mechanistically, we identified the G2/M checkpoint kinase WEE1 as a direct functional target of miR-22. The miR-22/WEE1 axis has been identified as both a reliable predictor of outcomes and a potential target for personalized therapeutic interventions.

2026-05-06 | GSE327216 | GEO

Whole-transcriptome sequencing of hepatocellular carcinoma biopsies (TACE study)

Project description:We performed a transcriptomic analysis of hepatocellular carcinomas (HCCs) and paired non-tumor biopsies to identify predictive biomarkers for response to transarterial chemoembolization (TACE). We identified several transcripts which are predictive of response to TACE.

| EGAS00001005558 | EGA

TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer

Project description:Transarterial chemoembolization (TACE) is an effective, minimally invasive therapy that is widely used for unresectable colorectal cancer liver metastases (CRC-LM) treatment. Chemoembolization, however, induces a hypoxic micro-environment, which increases neo-angiogenesis, and may promote early progression. For this reason, efficacy may be improved by associating TACE with an angiogenesis inhibitor, such as bevacizumab. The use of FOLFIRI associate to Bevacizumab is part of clinical practice and is commonly used for the therapy of patients with CRC-LM both wild type and mutant. This case-control observational study aim to compare patients treated with TACE using Irinotecan-loaded embolics followed by systemic Bevacizumab versus patients treated with FILFIRI+ Bevacizumab

| 2288833 | ecrin-mdr-crc

TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)

Project description:To date no randomized controlled trials have been completed that demonstrated whether TACE(Transarterial chemoembolization) is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in conversion resection rates and survival compared with chemotherapy (target therapy) alone for patients who failed with first-line chemotherapy.The primary objective of this trial is to determine conversion resection rates and survival for patients with colorectal cancer liver metastasis are treated with TACE plus chemotherapy ± target therapy, compared to chemotherapy ± target therapy in the 2nd, and 3rd line.

| 2292777 | ecrin-mdr-crc

Circulating miR-22 predicts TACE response and targets WEE1 in hepatocellular carcinoma

Project description:Circulating miR-22 predicts TACE response and targets WEE1 in hepatocellular carcinoma

| PRJNA1449977 | ENA

Heart Failure, DITPA and Captopril

Project description:Three weeks after infarction, age matched rats with large infarction by ECG criteria were randomly assigned to one of the three groups: 1) Treatment with Captopril for 21 days and a daily subcutaneous dose of DITPA for the last 10 days of treatment, 2) Treatment for 10 days with DITPA alone, 3) Control heart failure and 4) Sham-operated. Keywords: Drug Effects on Heart Failure

2006-07-21 | GSE4963 | GEO

A Positive Feedback Loop Between TKT and c-Myc Drives TACE Resistance In Hepatocellular Carcinoma

Project description:A Positive Feedback Loop Between TKT and c-Myc Drives TACE Resistance In Hepatocellular Carcinoma

| PRJNA1430878 | ENA

Expression data from skin biopsies in pateints with systemic sclerosis treated with anti-TGF-beta, fresolimumab

Project description:Systemic sclerosis is associated with skin fibrosis thought mediated by TGFb. This open label clinical trial examines the effect of TGFb inhibition on skin gene expression. Patients 1-9 received two doses 1 mg/kg dose of fresolimumab at baseline and 3 weeks; patients 10-19 received a single 5 mg/kg dose Patients with diffuse cutaneous systemic sclerosis within 2 years of first raynauds had skin biopsies before treatment and the 3-4 weeks, 7 weeks and 24 weeks after treatment with fresolimumab

2015-06-05 | E-GEOD-55036 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data